Evaxion biotech secures equity financing of up to $40 million from lincoln park capital

Copenhagen, denmark, june 07, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-powered immunotherapies, announced today that it has entered into a committed equity purchase agreement (the “agreement”) with lincoln park capital fund, llc (“lpc”), for the issuance and sale, from time to time, of up to $40 million of its american depositary shares (the “adss”), each of which represents one ordinary share, dkk 1 nominal value, of the company (the “ordinary shares”).
EVAX Ratings Summary
EVAX Quant Ranking